Research Coverage on Small and Micro-Cap Companies, Zacks Small Cap Research

Zacks Small Cap Research

Zacks Small Cap Research provides research coverage on small- and micro-cap companies that are “under-followed” or “under-valued” by Wall Street. We produce high quality equity research for the institutional and retail investor on microcap firms we believe are well positioned for future growth. The Zacks SCR analyst team has an average of 20 years of experience in investment research. We conduct significant due diligence in an effort to maintain the highest quality small-cap universe.

Research Coverage on Small and Micro-Cap Companies

Equity Bottom-Up

<ul><li>Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal (CRC), pancreatic, lung and breast cancers.</li><li>The company's primary indication is first line metastatic CRC in patients with Rat Sarcoma (RAS) mutations.</li><li>Onvansertib is an oral Polo-like kinase 1 (PLK1)-selective inhibitor that has synergies with bevacizumab & various chemotherapy regimens.</li></ul>

Cardiff is a clinical-stage, oncology-focused biotechnology company developing onvansertib against solid tumors including subsets of colorectal (CRC), pancreatic, lung and breast cancers.The company's primary indication is first line metastatic CRC in patients with Rat Sarcoma (RAS) mutations.Onvansertib is an oral Polo-like kinase 1 (PLK1)-selective inhibitor that has synergies with bevacizumab & various chemotherapy regimens.

Cardiff Oncology

CRDF: New CEO Presents Phase II Readout